A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

NEJM Publishes New Global Clinical Trial Findings Showing Potential Power of Investigational Medication to Improve ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 ...

Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

Brensocatib reduces the annualized rate of pulmonary exacerbations in patients with bronchiectasis compared to placebo, with rate ratios of 0.79 and 0.81 for 10 mg and 25 mg doses, respectively.

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

Neutrophils are the core airway inflammatory cell in bronchiectasis ... 15.2% had a history of chronic obstructive pulmonary disease, and 18.7% a history of asthma. Among the secondary endpoints ...